valproic acid has been researched along with 4-phenylbutyric acid in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 5 (27.78) | 29.6817 |
| 2010's | 7 (38.89) | 24.3611 |
| 2020's | 5 (27.78) | 2.80 |
| Authors | Studies |
|---|---|
| Bowes, AJ; Capretta, A; Gerritsma, D; Shi, Y; Werstuck, GH | 1 |
| Bora-Tatar, G; Dalkara, S; Dayangaç-Erden, D; Demir, AS; Erdem-Yurter, H; Yelekçi, K | 1 |
| Fass, DM; Ghosh, B; Haggarty, SJ; Hennig, K; Klein, PS; Lewis, TA; Maglathlin, RL; Mazitschek, R; Norton, S; Reis, SA; Shah, R; Zhao, WN | 1 |
| Madsen, AS; Olsen, CA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Armstrong, AJ; Collado, MS; Dillberger, JE; Figler, RA; Henke, BR; Hoang, SA; Johns, BA; Olson, MW; Pourtaheri, TD; Reardon, JE; Roper, TD; Taylor, JM; Wamhoff, BR | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Loffing, J; Moyer, BD; Reynolds, D; Stanton, BA | 1 |
| Kupisz, K; Polberg, K; Stepulak, A; Stryjecka-Zimmer, M | 1 |
| Chuang, DM; Leng, Y | 1 |
| Cassell, M; Lindsay, DS; Mitchell, SM; Reilly, CM; Strobl, JS | 1 |
| Carter, P; Fowler, JS; Hooker, JM; Kim, SW; King, P; Muench, L; Otto, N; Reid, AE; Shea, C; Volkow, ND; Win, K | 1 |
| Fedoročko, P; Ghantous, A; Halaburková, A; Herceg, Z; Jendželovský, R; Kovaľ, J | 1 |
| Nikouyan, N; Okhovat, MA; Ranjbaran, R; Ziari, K | 1 |
| Htun, MW; Koji, T; Shibata, Y; Soe, MT; Tun, N | 1 |
| Batjargal, K; Jimbo, EF; Tajima, T; Yamagata, T | 1 |
| Choi, DH; Choi, YK; Go, J; Kim, KS; Lee, CH; Park, HY; Rhee, M; Ryu, YK | 1 |
| Amanvermez, R; Arslan, G; Gün, S; Rzayev, E; Tiryaki, ES | 1 |
2 review(s) available for valproic acid and 4-phenylbutyric acid
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Histone deacetylase inhibitors as a new generation of anti-cancer agents].
Topics: Animals; Antineoplastic Agents; Depsipeptides; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Neoplasms; Phenylbutyrates; Tumor Cells, Cultured; Valproic Acid; Vorinostat | 2005 |
16 other study(ies) available for valproic acid and 4-phenylbutyric acid
| Article | Year |
|---|---|
Induction of GRP78 by valproic acid is dependent upon histone deacetylase inhibition.
Topics: Cell Line; Endoplasmic Reticulum Chaperone BiP; Gene Expression Regulation; Heat-Shock Proteins; Histone Deacetylase Inhibitors; Histones; Humans; Molecular Chaperones; Molecular Structure; Structure-Activity Relationship; Valproic Acid | 2007 |
Molecular modifications on carboxylic acid derivatives as potent histone deacetylase inhibitors: Activity and docking studies.
Topics: Caffeic Acids; Carboxylic Acids; Catalytic Domain; Chlorogenic Acid; Curcumin; Enzyme Inhibitors; HeLa Cells; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Models, Molecular; Molecular Structure; Protein Binding | 2009 |
Effect of Inhibiting Histone Deacetylase with Short-Chain Carboxylic Acids and Their Hydroxamic Acid Analogs on Vertebrate Development and Neuronal Chromatin.
Topics: | 2010 |
Substrates for efficient fluorometric screening employing the NAD-dependent sirtuin 5 lysine deacylase (KDAC) enzyme.
Topics: Benzamides; Coumarins; Enzyme Assays; Fluorometry; Furans; Humans; Isoenzymes; Kinetics; Lysine; Naphthols; Protein Processing, Post-Translational; Quinolines; Recombinant Proteins; Sirtuins; Structure-Activity Relationship; Substrate Specificity; Succinates; Suramin | 2012 |
Identification of 2,2-Dimethylbutanoic Acid (HST5040), a Clinical Development Candidate for the Treatment of Propionic Acidemia and Methylmalonic Acidemia.
Topics: Acyl Coenzyme A; Amino Acid Metabolism, Inborn Errors; Animals; Area Under Curve; Butyrates; Cells, Cultured; Dogs; Drug Evaluation, Preclinical; Half-Life; Hepatocytes; Humans; Mice; Models, Biological; Propionic Acidemia; Rats; ROC Curve; Structure-Activity Relationship | 2021 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
PBA increases CFTR expression but at high doses inhibits Cl(-) secretion in Calu-3 airway epithelial cells.
Topics: Butyrates; Cell Line; Chlorides; Cystic Fibrosis Transmembrane Conductance Regulator; Dose-Response Relationship, Drug; Electric Conductivity; Epithelial Cells; Humans; Phenylbutyrates; Respiratory System; Sodium-Potassium-Exchanging ATPase; Valproic Acid | 1999 |
Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity.
Topics: Acetylation; alpha-Synuclein; Animals; Anticonvulsants; Antimanic Agents; Cells, Cultured; Cerebellum; Cerebral Cortex; Glutamic Acid; Histone Deacetylase Inhibitors; Histones; Hydroxamic Acids; Neuroprotective Agents; Oligonucleotides, Antisense; Phenylbutyrates; Promoter Regions, Genetic; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Sprague-Dawley; RNA, Small Interfering; Ubiquitin-Conjugating Enzymes; Valproic Acid | 2006 |
Scriptaid and suberoylanilide hydroxamic acid are histone deacetylase inhibitors with potent anti-Toxoplasma gondii activity in vitro.
Topics: Animals; Antiprotozoal Agents; Butyrates; Cattle; Cell Line; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Hydroxylamines; Inhibitory Concentration 50; Niacinamide; Parasitic Sensitivity Tests; Phenylbutyrates; Quinolines; Toxoplasma; Valproic Acid; Vitamin B Complex; Vorinostat | 2007 |
Whole-body pharmacokinetics of HDAC inhibitor drugs, butyric acid, valproic acid and 4-phenylbutyric acid measured with carbon-11 labeled analogs by PET.
Topics: Animals; Blood Proteins; Brain; Butyric Acid; Carbon Radioisotopes; Female; Histone Deacetylase Inhibitors; Isotope Labeling; Papio; Phenylbutyrates; Positron-Emission Tomography; Radiochemistry; Tissue Distribution; Valproic Acid | 2013 |
Histone deacetylase inhibitors potentiate photodynamic therapy in colon cancer cells marked by chromatin-mediated epigenetic regulation of
Topics: Anthracenes; Antineoplastic Agents; Cell Line, Tumor; Chromatin; Colonic Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; DNA Methylation; Drug Resistance, Neoplasm; Drug Synergism; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Perylene; Phenylbutyrates; Photochemotherapy; Valproic Acid | 2017 |
The effect of histone deacetylase inhibitors on AHSP expression.
Topics: Blood Proteins; Gene Expression Regulation; Hemoglobinopathies; Histone Deacetylase Inhibitors; Humans; K562 Cells; Kruppel-Like Factor 4; Molecular Chaperones; Phenylbutyrates; Real-Time Polymerase Chain Reaction; Valproic Acid | 2018 |
Histone deacetylase inhibitors suppress transdifferentiation of gonadotrophs to prolactin cells and proliferation of prolactin cells induced by diethylstilbestrol in male mouse pituitary.
Topics: Acetylation; Animals; Apoptosis; Cell Proliferation; Cell Transdifferentiation; Diethylstilbestrol; Gonadotrophs; Histone Deacetylase Inhibitors; Histones; Injections, Intraperitoneal; Lactotrophs; Male; Mice; Mice, Inbred ICR; Phenylbutyrates; Pituitary Gland; Rabbits; Valproic Acid | 2019 |
Effect of 4-phenylbutyrate and valproate on dominant mutations of WFS1 gene in Wolfram syndrome.
Topics: Animals; Apoptosis; Cells, Cultured; Endoplasmic Reticulum Stress; Gene Expression Regulation; Genes, Dominant; HEK293 Cells; HeLa Cells; Humans; Membrane Proteins; Mice; Mice, Transgenic; Mutation; Phenylbutyrates; Protein Transport; Response Elements; Tissue Distribution; Transcription Factor CHOP; Transcriptional Activation; Transfection; Valproic Acid; Wolfram Syndrome | 2020 |
Sodium phenylbutyrate reduces repetitive self-grooming behavior and rescues social and cognitive deficits in mouse models of autism.
Topics: Animals; Antineoplastic Agents; Autism Spectrum Disorder; Brain; Cognitive Dysfunction; Disease Models, Animal; Female; Grooming; Male; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Mice, Transgenic; Phenylbutyrates; Social Behavior; Stereotyped Behavior; Valproic Acid | 2021 |
4-Phenylbutyric Acid Plus Valproic Acid Exhibits the Therapeutic and Neuroprotective Effects in Acute Seizures Induced by Pentylenetetrazole.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Epilepsy; Male; Neuroprotective Agents; Pentylenetetrazole; Phenylbutyrates; Rats; Seizures; Valproic Acid | 2022 |